-
Role of the intestinal
tight junction modulator zonulin in the pathogenesis of type I diabetes in BB
diabetic-prone rats.
-
argeting
beta-catenin by celecoxib (Celebrex) as an anti-cancer mechanism of action and
as a lead for the identification of improved oncology agents
-
MPEP a
prototypical glutamate (mGlu5) receptor antagonist with similar anxiolytic
efficacy compared to diazepam but with reduced cognitive adverse effects.
-
Eisai's retinoic
acid (RAR)-alpha receptor agonist as a candidate therapy for the treatment of
lupus nephritis
-
SOCS1 silencing
dramatically increases the anti-cancer efficacy of dendritic cell vaccines
-
Novel 3-oxa
lipoxin A4 analogues with enhanced chemical and metabolic stability have
anti-inflammatory activity in vivo.
-
Exploiting the
peptide uptake transporters PEPT1 and PEPT2 to improve drug absorption and
targeting
-
MBD2 inhibition
identified as a selective strategy for reducing tumor growth
-
The effects of
insulin on airway function: repercussions for intra-tracheal insulin delivery
and for asthma therapeutics
-
Janus tyrosine
kinase 3 inhibition for the prevention of transplant rejection
-
NVP-LAQ824 a novel
histone deacetylase inhibitor
-
Cx43 as a target
for improved wound healing
-
Development of
GSK-3 inhibitors by GlaxoSmithKline and by Johnson & Johnson
-
HDAC7: A novel
target for autoimmune disorders
-
Ki-67 as a target
for anticancer strategies
-
Successful gene therapy of pulmonary hypertension
-
MAPK/ERK-kinase inhibitors as a promising strategy for the treatment of neuropathic pain
-
Retinoids as candidate targets for alzheimer’s disease treatment
-
PI3K inhibitors: Targeting multiple tumor progression pathways
-
Gap junctions: The future of cancer therapy and prevention?
-
Advances in Kv1.3 channel research
-
Sigma(1) agonists offer hope to Alzheimer’s disease patients
-
BMS-191095, a
K(ATP) channel opener with improved cardioprotective properties
-
Survivin as a target for cancer therapy
-
GSK-3: A target for Alzheimer's disease
-
Melatonin: An emerging target for multiple conditions
-
Stat5: A target for immunological and neoplastic disease
-
Protein kinase D: A signalling molecule with multiple therapeutic implications
-
Leptin: a target for a growing list of conditions
-
The interleukin-10 family of cytokines
-
Serotonin 5-HT7 receptor antagonists as candidate migraine therapies
-
PLA2, an unexploited target for inflammation and infectious diseases
-
Hemostasis modulators: The next generation of anticancer molecules?
-
GSK-3 inhibitors for diabetes, Alzheimer's disease, stroke and manic depression
-
The broad based therapeutic potential of PARP-1 inhibitors
-
Mixed
kappa opioid/somatostatin ligands as treatments for cancer progression and
pain
-
Protecting
against Alzheimer's disease with Humanin
-
Endostatin as a lead
anti-angiogenic treatment
-
Histone deacetylase inhibitors: An emerging class of anti-cancer drugs
LeadDiscovery and BioPortfolio
aims to provide reliable, insightful analysis on the biotechnology industry.
However, this information is provided "as is" and no
representations or warranties either express or implied of completeness,
accuracy, or of any other nature are made with respect to this information.
This information is neither an offer to sell nor a solicitation to buy the
securities of any company. This information contains forward-looking
statements, which involve risks and uncertainties which may not be listed.
The biotechnology industry is an emerging industry and the securities of the
companies mentioned in this report have a very high degree of risk and
volatility. For this reason, this information is supplied on the condition
that the reader will make his or her own determination as to its suitability
for any purpose prior to any use of this information. The employees and
officers of LeadDiscovery and BioPortfolio may hold positions in some or all
of the stocks discussed in this report.
This
abstract has been produced by LeadDiscovery Ltd. Founded by life scientists
for life scientists we aim to help industry identify cutting edge drug
discovery options and academic/biotech institutions maximize the potential
of their research. Abstracts strictly reflect the opinion of LeadDiscovery's
editorial panel. While all reasonable efforts are made to ensure the
accuracy of information provided LeadDiscovery and the publisher
BioPortfolio, takes no responsibility for incorrect or misleading
information. LeadDiscovery is designed for educational and drug development
purposes only and is not intended or designed to offer medical advice or
advice of any sort, and must not be used for such purpose. The information
provided through LeadDiscovery and BioPortfolio should not be used for
diagnosing or treating a health problem or a disease and no reliance should
be placed on any information contained in this abstract or elsewhere on
LeadDiscovery's and BioPortfolio's website. It is not intended to be a
substitute for professional care. If you have or suspect you may have a
health problem, you should consult your physician or other health care
provider.